MarketCap
Facebook
X
Telegram
Genfit SA Gesamtes Eigenkapital | GNFT
Gesamtes Eigenkapital Jährlich Genfit SA
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -16.2 M | 84.1 M | 20.9 M | 101 M | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 101 M | -16.2 M | 47.6 M |
Gesamtes Eigenkapital Vierteljährlich Genfit SA
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 119 M | - | - | - | -16.4 M | - | - | - | 84.1 M | - | - | - | 20.9 M | - | - | - | 101 M | - | - | - | 143 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 143 M | -16.4 M | 75.3 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
7.06 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
391 M | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
24.3 M | - | 1.35 % | $ 17.8 M | China |
 |
Synthetic Biologics
SYN
|
15.4 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
597 M | - | - | $ 2.02 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-95.5 M | $ 1.19 | 5.31 % | $ 14.5 M | USA |
 |
Burford Capital Limited
BUR
|
2.45 B | $ 4.37 | 0.23 % | $ 958 M |  Britain |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | China |
 |
BeyondSpring
BYSI
|
-32.2 M | $ 0.84 | 34.27 % | $ 34.5 M | USA |
 |
Corner Growth Acquisition Corp.
COOL
|
-297 K | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-3.89 M | - | -13.47 % | $ 169 M |  France |
 |
Cerus Corporation
CERS
|
64.2 M | $ 2.98 | 4.93 % | $ 568 M | USA |
 |
Compugen Ltd.
CGEN
|
103 M | $ 2.41 | 4.17 % | $ 225 M |  Israel |
 |
CureVac N.V.
CVAC
|
697 M | - | - | $ 867 M |  Germany |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-14.6 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
727 M | - | - | $ 4.9 B | Britain |
|
Galera Therapeutics
GRTX
|
3.97 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
2.67 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
472 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M | Germany |
|
Champions Oncology
CSBR
|
3.94 M | $ 5.1 | 2.63 % | $ 70.5 M | USA |
 |
Affimed N.V.
AFMD
|
57.8 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-13.7 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
4.32 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
5.28 M | $ 3.98 | 1.86 % | $ 2.66 M | USA |
 |
Generation Bio Co.
GBIO
|
86.2 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
AnaptysBio
ANAB
|
37.2 M | $ 58.47 | 4.37 % | $ 1.68 B | USA |
 |
Anika Therapeutics
ANIK
|
143 M | $ 21.5 | 1.56 % | $ 308 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
6.84 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
1.38 B | - | - | $ 3.37 B | China |
 |
Aurinia Pharmaceuticals
AUPH
|
581 M | $ 15.47 | 1.91 % | $ 2.08 B | Canada |
 |
GlycoMimetics
GLYC
|
203 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AVROBIO
AVRO
|
251 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bicycle Therapeutics plc
BCYC
|
610 M | $ 3.9 | 0.24 % | $ 270 M | Britain |
 |
Beam Therapeutics
BEAM
|
1.24 B | $ 26.75 | 0.91 % | $ 2.65 B | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
6.09 B | $ 67.36 | 0.99 % | $ 12.9 B | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |